Abstract
Weekly low dose methotrexate is an established treatment for rheumatoid arthritis, but its use in elderly people has not been adequately examined. The aim of this study was to evaluate its safety in elderly patients with rheumatoid arthritis. A retrospective review of the clinical records of rheumatoid arthritis patients over the age of 65 attending a rheumatology unit was conducted. Eligible patients were followed for at least two years and treated with methotrexate in a dose of 7.5 mg/week while being maintained on concurrent treatment. Thirty three patients were studied. Their mean age was 78.8 years; 32 were female and one was male. Treatment was discontinued in four patients, two because of raised serum liver enzymes and two because of gastrointestinal irritation. No serious adverse events were reported. After two years, haemoglobin levels increased from a mean (SD) of 12.4 (1.3) g/dl to 13.0 (1.1) g/dl (r = 0.226, p < 0.005). The white blood count was significantly reduced from 7.9 (1.8) × 109/l to 6.8 (1.7) × 109/l (r = 0.184, p < 0.05). No episodes of neutropenia or agranulocytosis were observed. There was a non-significant decrease in platelet count. The erythrocyte sedimentation rate decreased from 56.8 (30.8) to 35.2 (24.6) mm/h (r = 0.246, p < 0.01). In conclusion, low methotrexate treatment in elderly patients appears to be safe. Routine determination of serum liver enzymes and renal function may reduce individual risk. Keywords: methotrexate; elderly; safety
Full Text
The Full Text of this article is available as a PDF (70.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bologna C., Viu P., Jorgensen C., Sany J. Effect of age on the efficacy and tolerance of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1996 May;35(5):453–457. doi: 10.1093/rheumatology/35.5.453. [DOI] [PubMed] [Google Scholar]
- Bressolle F., Bologna C., Kinowski J. M., Arcos B., Sany J., Combe B. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol. 1997 Oct;24(10):1903–1909. [PubMed] [Google Scholar]
- Buchbinder R., Hall S., Sambrook P. N., Champion G. D., Harkness A., Lewis D., Littlejohn G. O., Miller M. H., Ryan P. F. Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice. J Rheumatol. 1993 Apr;20(4):639–644. [PubMed] [Google Scholar]
- Chan K. W., Felson D. T., Yood R. A., Walker A. M. Incidence of rheumatoid arthritis in central Massachusetts. Arthritis Rheum. 1993 Dec;36(12):1691–1696. doi: 10.1002/art.1780361207. [DOI] [PubMed] [Google Scholar]
- McKendry R. J., Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol. 1993 Nov;20(11):1850–1856. [PubMed] [Google Scholar]
- Nesher G., Moore T. L. Rheumatoid arthritis in the aged. Incidence and optimal management. Drugs Aging. 1993 Nov-Dec;3(6):487–501. doi: 10.2165/00002512-199303060-00003. [DOI] [PubMed] [Google Scholar]
- Tett S. E., Triggs E. J. Use of methotrexate in older patients. A risk-benefit assessment. Drugs Aging. 1996 Dec;9(6):458–471. doi: 10.2165/00002512-199609060-00008. [DOI] [PubMed] [Google Scholar]
- Weinblatt M. E. Efficacy of methotrexate in rheumatoid arthritis. Br J Rheumatol. 1995 Nov;34 (Suppl 2):43–48. [PubMed] [Google Scholar]
- Weinblatt M. E., Maier A. L., Fraser P. A., Coblyn J. S. Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J Rheumatol. 1998 Feb;25(2):238–242. [PubMed] [Google Scholar]